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Abstract
Although genetic variation among humans in their susceptibility to infectious diseases has long been appreciated, little
focus has been devoted to identifying patterns in levels of variation in susceptibility to different diseases. Levels of genetic
variation in susceptibility associated with 40 human infectious diseases were assessed by a survey of studies on both
pedigree-based quantitative variation, as well as studies on different classes of marker alleles. These estimates were
correlated with pathogen traits, epidemiological characteristics, and effectiveness of the human immune response. The
strongest predictors of levels of genetic variation in susceptibility were disease characteristics negatively associated with
immune effectiveness. High levels of genetic variation were associated with diseases with long infectious periods and for
which vaccine development attempts have been unsuccessful. These findings are consistent with predictions based on
theoretical models incorporating fitness costs associated with the different types of resistance mechanisms. An appreciation
of these observed patterns will be a valuable tool in directing future research given that genetic variation in disease
susceptibility has large implications for vaccine development and epidemiology.
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Introduction
‘It seems likely that when a species is subjected to a series of
attacks by an evolving parasite it may be forced along a path
of structural change by its temporarily successful acquisitions
of immunity. But in the end it may be driven, so to say, into
a corner, where further immunity involves structural
changes which are disastrous to it in its everyday life.’
J.B.S. Haldane (1932) The Causes of Evolution.
In the middle of the last century, Haldane made his now-
famous assertion that infectious disease acts as a selective force in
human populations, suggesting that heterozygosity for certain
blood disorders might confer a selective advantage in the form of
resistance to malaria infection [1–3]. Empirical evidence in
support of this prediction soon followed [4–7], even though this
assertion was initially met with strong opposition within the
scientific community (J. J. Murray, personal communication).
Since the post-genomic era, research programs have been built
around the search for genetic diversity associated with infectious
disease, the findings of which have been documented in many
reviews and texts [8–16]. Highlighting the importance of a
genetic component to disease susceptibility, Sorensen et al. (1988)
showed that adult adoptees were five times more likely to die
from an infectious disease if their biological parent also died from
an infection; this increased risk associated with infectious disease
was higher than that for either cardiovascular disease or cancer
[17].
Infectious disease remains a leading cause of death in many
parts of the world, and efforts to identify genetic variation in
disease susceptibility have been motivated by the implications for
disease control strategies. Discoveries of genetic variation open up
possibilities of pinpointing resistance pathways for targeted
therapies and for personalized pharmaceuticals. Strong genetic
components associated with susceptibility to natural infections may
also be responsible for differences in vaccine response [18,19], and
point to the potential benefits of a more personalized vaccine
approach [20,21]. Genetic variation in susceptibility is also likely
important for zoonotic diseases, a fact that was underscored by
reports of H5N1 influenza infections clustering in family units,
launching concerns that groups of susceptible individuals might
provide zoonotic pathogens with a gateway into human popula-
tions [22,23].
In contrast to the high levels of genetic variation in susceptibility
to some infections, other well-characterized diseases, such as
mumps, appear to be associated with very little variation in
susceptibility [24,25]. Nevertheless, there has been little attempt to
develop a theoretical framework for understanding and predicting
patterns in the levels of genetic variation for susceptibility to
different diseases. For example, diseases with strong effects on host
fitness, high prevalence levels, large geographic ranges, or long
histories in human populations may generate high levels of
transient genetic variation in susceptibility, but they may also lead
to the loss of susceptibility genes over time and therefore eventual
loss of variation depending on the costs. Alternatively, genetic
variation in susceptibility may be the result of selection for multiple
resistance mechanisms generated by correspondingly variable
pathogen genotypes, as occurs in many gene-for-gene systems in
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29089plants. Furthermore, heterozygote advantage or pleiotropic effects
with alternate resistance mechanisms could contribute to genetic
variation in susceptibility. More recently, theoretical studies have
proposed that the shape of the resistance-fitness trade-off curve is
an important determinant of genetic diversity [26], but there has
been no explicit test of this hypothesis.
In the present study, we estimate the relative magnitude of
genetic variation in susceptibility to human diseases and relate this
to disease characteristics in order to investigate the possible
evolutionary forces responsible for the observed patterns in genetic
diversity. We consider alternative hypotheses by focusing on
measures of traits related to disease severity, epidemiological
scope, and immune system effectiveness (Fig. 1). This study
represents the first comparative analysis of a broad range of
human pathogens seeking to identify evolutionary determinants of
genetic variation in disease susceptibility.
Results
We identified 46 diseases that met all of the criteria for inclusion
in the study (see Methods). A total of 40 diseases were included in
the final analyses because for six diseases, we could not find any
scientific literature evaluating genetic variation in susceptibility
(Table 1). The diseases included in the analysis were caused by
diverse human pathogens (35% viruses, 32% bacteria, 12%
protozoa, 5% fungi, and 15% helminths) with diverse transmission
modes (10% sexual contact, 47% close contact, 30% indirect
contact, and 12% vectors).
Univariate analyses of disease characteristics
We first conducted univariate analyses to investigate the effects
of the individual disease characteristics on variation in suscepti-
bility. Variation in susceptibility was significantly negatively
correlated with effectiveness of vaccine development (rs=20.41,
p=0.008; Fig. 2), with low levels of genetic variation for diseases
with an effective vaccine. Amebiasis, trichuriasis, ascariasis, and
strep throat were among the diseases with high levels of variation
in susceptibility for which no vaccines have been successfully
developed. Diseases successfully combated by vaccines, such as
hepatitis A, rubella, mumps, and pertussis, exhibited low levels of
variation in susceptibility.
Marginally significant correlations were observed in suscepti-
bility with duration of the infectious period (rs=0.26, p=0.09;
Fig. 3A) and with mortality (rs=20.29, p=0.07; Fig. 3B).
Diseases exhibiting high levels of genetic variation in suscepti-
bility were generally those with long infectious periods, such as
herpes simplex viruses (HSV-1 and HSV-2), leprosy, hepatitis C,
and gastric ulcers. Diseases with the lowest levels of variation
were of short duration, and included hepatitis A, rubella,
mumps, influenza, and pertussis. Still, some diseases with short
infectious periods showed evidence for high levels of genetic
variation, including cholera and dengue fever. Diseases that
cause high mortality, such as African sleeping sickness, cholera,
streptococcal pneumonia, and smallpox were associated with
lower levels of variation in susceptibility than were more benign
infections, such as candidiasis, trichuriasis, mononucleosis and
elephantiasis.
Figure 1. Diagram showing major disease characteristics and their component traits that were investigated in relation to genetic
variation in infectious disease susceptibility.
doi:10.1371/journal.pone.0029089.g001
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susceptibility were significantly different among the classes of
disease agents (F4,35=2.82, p=0.04, Fig. 4). There tended to be
lower levels of variation in susceptibility to diseases caused by
RNA viruses than to diseases caused by DNA viruses and bacteria,
though the pairwise effects between them were not significant (at
the a=0.05 level in a Tukey HSD test correcting for multiple post
hoc comparisons).
Levels of variation in susceptibility were not significantly
different among the disease transmission modes (F3,36=1.59,
p=0.21).
Multivariate analysis of disease characteristics
Because the three major traits of interest namely disease
severity, epidemiological scope and immune effectiveness (Fig. 1)
were each measured by several inter-correlated explanatory traits,
we used principal components analysis (PCA) to identify
combinations of these traits (represented by principal component
scores) that contributed independently to each variable. We then
tested whether the first two PCA scores for each of these major
traits explained genetic variation in susceptibility. This was done
using an ANCOVA, with disease agent and transmission mode as
class variables, and a backward selection procedure that
sequentially removed terms contributing least to the variance in
susceptibility. This analysis only retained immune effectiveness
and disease agent class as factors contributing to genetic variation
in susceptibility (p,0296, and p,0.0150 respectively, Type III
sums of squares).
As only immune effectiveness was significant, we performed a
multiple regression of level of variation in susceptibility on the
individual immune system traits. This analysis indicated that the
duration of the infectious period and effectiveness of vaccine
development, as well as an interaction between these terms, were
highly significant predictors of variation in susceptibility (Table 2).
A plot of the interaction between the duration of the infectious
period and the effectiveness of vaccine development showed that
high levels of genetic variation in susceptibility were associated
with diseases of longer duration, particularly for diseases with
effective vaccine development (Fig. 5). Very low levels of genetic
variation in susceptibility were associated with diseases with short
infectious periods and for which effective vaccines have been
developed. However, where vaccine development had been
Table 1. List of diseases and corresponding pathogen species
included in the analysis.
Disease Pathogen Acronym
African sleeping sickness Trypanosoma brucei gambiense ASS
Amebiasis Entamoeba histolytica AME
Ascariasis Ascaris lumbricoides ASC
Candidiasis Candida albicans CAN
Chickenpox Varicella zoster virus CHI
Cholera Vibrio cholerae CHO
Cryptosporidiosis Cryptosporidium parvum CRY
Dengue Fever Dengue virus DEN
Diphtheria Corynebacterium diphtheriae DIP
Elephantiasis Wuchereria bancrofti ELE
Gastric ulcers Helicobacter pylori ULC
Giardiasis Giardia lamblia GIA
Gonorrhea Neisseria gonorrhoeae GON
Hepatitis A Hepatitis A virus HPA
Hepatitis B Hepatitis B virus HPB
Hepatitis C Hepatitis C virus HPC
Herpes simplex 1 Herpes simplex virus-1 HS1
Herpes simplex 2 Herpes simplex virus-2 HS2
Hookworm Necator americanus HOO
Influenza Influenza A virus FLU
Leprosy Mycobacterium leprae LEP
Malaria Plasmodium falciparum MAL
Measles Measles virus MEA
Meningitis Haemophilus influenzae HIB
Meningitis Neisseria meningitidis NMG
Mononucleosis Epstein-Barr virus MON
Mumps Mumps virus MUM
Pertussis Bordetella pertussis PER
Pneumonia Streptococcus pneumoniae STP
Poliomyelitis Poliovirus POL
Ringworm Trichophyton rubrum RIN
Riverblindness Onchocerca volvulus RIV
Rubella Rubella virus RUB
Schistosomiasis Schistosoma mansoni SCH
Smallpox Variola virus SMA
Strep throat Streptococcus pyogenes STT
Trachoma Chlamydia trachomatis CHL
Trichuriasis Trichuris trichiura TRI
Tuberculosis Mycobacterium tuberculosis TUB
Typhoid fever Salmonella typhi TYP
Acronyms for each disease are as used in the figures.
doi:10.1371/journal.pone.0029089.t001
Figure 2. Relationship between levels of variation in suscep-
tibility and effectiveness of vaccine development, as rank
scores (p=0.008). See Table 1 for key to acronyms for the individual
diseases.
doi:10.1371/journal.pone.0029089.g002
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showed substantial variation in susceptibility.
Discussion
The present study indicates that there are large differences
among infectious diseases in the levels of genetic variation for
susceptibility to those diseases. The differences we found, at least
with regard to relative levels of variation, were consistent with
previous estimates carried out by independent observers, and with
the coverage attributed to given diseases in textbooks reviewing
evidence for genetic variation (see Methods section on Validation).
Comparisons of our estimates with these independent assessments
suggest consensus on high levels of genetic variation in
susceptibility to diseases such as leprosy, mononucleosis, and
gastric ulcers, intermediate levels with diseases including polio,
chickenpox, and smallpox, and low levels of variation in
susceptibility to hepatitis A, mumps, and pertussis.
The levels of variation in susceptibility were strongly associated
with particular disease traits. The disease characteristics that
consistently predicted levels of variation in susceptibility were
those that reflected the effectiveness of the immune response to
disease. This was true for all diseases and independent of the type
of pathogen, its transmission mode, or levels of disease severity. As
Figure 3. Relationship between levels of variation in suscep-
tibility and disease traits for 40 human diseases. (A) Duration of
infectious period, as log days (p=0.09). (B) Disease-induced mortality, as
log case fatality rate (p=0.07). See Table 1 for key to acronyms for the
individual diseases.
doi:10.1371/journal.pone.0029089.g003
Figure 4. Levels of variation in susceptibility among different
classes of disease agents (F4,35=2.82, p=0.04). DNA=DNA
viruses, RNA=RNA viruses, Bact=bacteria, Uni=unicellular, i.e. proto-
zoans. Multi=multicellular, i.e. fungi and helminths. Boxes depict inter-
quartile ranges (IQR), and bold horizontal lines indicate medians for
each group. Whiskers extend from the minimum to maximum value.
Circle represents an outlier, defined as a value smaller than 1.5 times the
IQR from the first quartile.
doi:10.1371/journal.pone.0029089.g004
Table 2. Analysis of covariance on levels of variation in
susceptibility.
Source d.f. Type III SS Fp
Agent 4 1.46 3.13 0.029
Transmission 3 0.52 1.51 0.234
Duration 1 1.23 10.61 0.002
Vaccine 1 2.80 24.00 ,.0001
Duration*Vaccine 1 1.25 10.77 0.002
Error 29 3.38
Total 39 10.22
Agent=disease agent (as a class variable), Transmission=transmission mode
(as a class variable), Duration=duration of the infectious period,
Vaccine=effectiveness of vaccine development.
doi:10.1371/journal.pone.0029089.t002
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disease characteristics with independent evaluations. Thus, there
was strong agreement between our estimates and those collected
independently by an upper-level class for all of the comparable
disease traits (unpublished data). Therefore whereas caution is
needed in interpreting the data for any specific disease (and these
interpretations may be approximate), the consistency of the
estimates across several studies indicates that the overall patterns
found in this study are robust.
While our analyses indicate that characteristics related to the
effectiveness of the adaptive immune response are important
determinants of levels of variation in susceptibility, the traits
related to the immune response were not equally powerful
predictors. The finding that the relative success of vaccine
development was the trait most strongly correlated with levels of
variation in susceptibility seems curious, as successful vaccine
development cannot be, in and of itself, an evolutionary
determinant; the introduction of vaccination regimes is too recent
to have substantially influenced extant patterns of human genetic
variation. Rather, it is likely that estimates for the trait ‘vaccine
development’ best reflect the effectiveness of an inducible immune
response to a given infectious disease organism, and that vaccines
are most easily developed against a disease for which there is also a
natural long-lasting immune response.
The observed patterns can be interpreted in the light of several
hypotheses that are not necessarily exclusive, nor even the only
possibilities. We consider these in turn.
Fitness effects
It could be argued that diseases with strong fitness effects on
infected individuals (high mortality and sterility) and with a large
epidemiological impact (high lifetime risk of infection, large
geographic range, and long historical record of disease in human
populations) should be associated with high levels of genetic
variation. However, our data do not support this hypothesis, as
characteristics estimating disease severity and epidemiological
scope were not strong predictors of levels of genetic variation.
While severe and/or widespread diseases might generate genetic
variation by producing strong selection for resistance alleles,
diseases with extreme fitness effects may ultimately eliminate
variation by fixing resistance alleles. Therefore, the relationship
between disease severity and epidemiological traits and resulting
levels of genetic variation in susceptibility may be non-linear, but
we also found no evidence of this. There was no trend in the data
suggesting that diseases of intermediate severity (representing
perhaps transient polymorphisms in resistance) had the greatest
amount of genetic variation.
Variation in pathogen genotypes
The most polymorphic gene complex in the vertebrate genome
is the major histocompatibility complex (MHC), and population
geneticists have debated at length the forces that maintain
variation in these immune-related genes [27,28]. While it is
generally agreed that this diversity is likely to be maintained by
pathogen-mediated selection, the specific mechanisms (e.g.
overdominance, rare-allele advantage, and fluctuating selection)
often generate similar predictions that are difficult to distinguish,
so there is no consensus about which mechanisms are the most
important or the relevance of pathogen genotypic variation
[29,30]. Unfortunately, it was not possible to compare the levels
of genetic diversity in the pathogens causing the different diseases
in this study for three reasons. First, although there is abundant
Figure 5. Levels of genetic variation in susceptibility in relation to the effectiveness of vaccine development and the duration of
the infectious period. Color key indicates level of variation in susceptibility. Purple/blue corresponds to low levels of variation in susceptibility,
while yellow/orange corresponds to high levels of variation in susceptibility. Response surface is based on a multiple regression model (see text for
explanation).
doi:10.1371/journal.pone.0029089.g005
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for example, strain differences or antigenic variants), it was usually
unclear how meaningful this variation was for selection on human
genotypes. Second, it was difficult to obtain valid comparative
measures of strain differences across pathogen taxa as different as,
say, viruses and helminths. Third, any impact of pathogen
variation on host genetic variation requires the presence of host
genotype6pathogen genotype interaction in infectivity or disease
expression. Evidence of such interactions (analogous to the gene-
for-gene systems seen in crop plants) would normally require
experimental cross-inoculation experiments, and are therefore
difficult to obtain except where there are clear and well-
understood observable differences. One example, albeit at the
species level, is the lower susceptibility of Duffy blood groups to
malaria caused by Plasmodium vivax, yet continued susceptibility to
Plasmodium falciparum.
Resistance costs
Mathematical models of host-parasite co-evolution show that
that genetic variation in the host can be maintained in the absence
of pathogen variation and over a wide range of costs (manifested in
the absence of disease as lower fitness of resistant individuals
compared to susceptibles), particularly when alleles confer extreme
phenotypes of susceptibility in the population [31,32]. Costs of
resistance mechanisms have often been assumed, as it seems
intuitive that the energetic expense of mounting such resistance
must detract from a finite pool of resources that could otherwise be
employed for survival or reproduction. Resistance costs have been
demonstrated in a number of experimental systems [33–37], but
only rarely in nature [38]. Fitness costs to genes that result in
various forms of thalassemia and provide resistance to malaria are
also well known [39,40].
More recent studies have expanded single-locus models of costs
to consider the more likely scenario in which relative susceptibility
to disease is a complex quantitative trait determined by allelic
variation at multiple loci. The resulting selective forces depend
heavily on the shape of the resistance-fitness trade-off curve, and
this shape is a crucial evolutionary determinant of the resulting
level of genetic variation in resistance [26,41]. Costs can be
accelerating, such that increases in resistance become increasingly
costly, or decelerating, where accumulating resistance becomes
decreasingly costly. When the trade-off curve is accelerating, there
will be a stabilizing component in the resulting selection gradient
that will reduce genetic variation. Alternatively, a decelerating
trade-off will result in disruptive selection and increased genetic
diversity.
Although the trade-off curves have not been characterized for
any human diseases (see [38] for an experimental study with a
plant pathogen), the shapes of these curves can be inferred from
our understanding of the mechanisms conferring resistance.
Specifically, mechanisms associated with the adaptive immune
system should have accelerating costs, as the basic immune system
costs are generally similar and low among individuals in the
absence of disease, and therefore further genetic gains in resistance
may require costly structural changes. Alternatively, where the
inducible immune response is ineffective, resistance mechanisms
may require constitutive mutations, which are likely to be costly.
Based on these inferences, we can predict that where the adaptive
immune system is effective, there will be accelerating resistance-
fitness trade-offs which will generate stabilizing selection and low
levels of genetic variation. On the other hand, the decelerating
trade-off associated with ineffective adaptive immune responses
should lead to destabilizing selection and high levels of genetic
variation.
Our findings are consistent with these expectations. Diseases
that evoke effective adaptive immune responses, as evidenced by
traits such as successful vaccine development and short infectious
periods, result in low levels of variation in susceptibility in their
hosts. Likewise, diseases that circumvent the adaptive immune
system, defying attempts at vaccine development and exhibiting
long infectious periods, should show decelerating costs, and indeed
are associated with high levels variation in susceptibility. As
resistance-fitness trade-off curves have not been characterized for
any human diseases to date, we cannot definitively link the
differences in levels of genetic variation with differences in the
trade-off curves; however, there is precedence in the literature for
using observed patterns of genetic variation in susceptibility to
imply the shapes of these trade-offs [42]. Measuring such trade-off
curves for human diseases has hardly been contemplated, but
presents an important research challenge.
Our study also provided important methodological lessons (see
Information S1 for further discussion). It was clear that quantifying
levels of genetic variation in disease susceptibility in human
populations requires a comprehensive approach. Currently, the
majority of studies on variation in susceptibility are case-control
association studies that report the magnitudes of allelic effects, with
the primary goal of pinpointing important loci involved in
pathogenesis. For estimation of how much these loci contribute
to overall genetic variation, information is additionally required on
the allele frequencies of the loci as well as the risk of exposure to
the disease in the population being investigated. Usually, such
information is not reported. If non-candidate gene markers such as
SNPs are being used, estimates of the locus-specific contribution to
overall variation in susceptibility raise further methodological
issues that have been discussed under the rubric of so-called
‘‘missing heritability’’ [43]. Databases of SNP data and of data
pertaining to specific diseases are beginning to emerge, but we
know of no single database that includes both pedigree-based and
marker-based data for a large array of diseases.
Perhaps most surprising, was the difficulty of obtaining good
quantitative data on many of the disease characteristics (see
Information S1, for further discussion). This difficulty has also
been mentioned in previous comparative studies of human
sexually transmitted infectious diseases [44]. One would imagine
that the characteristics of different human diseases would be well
understood, and that there would be ‘canonical’ information on
these diseases in readily available databases. Some steps have been
made towards this in recent databases such as GIDEON, where
comprehensive information is available especially on geographical
distribution and prevalence; this has been invaluable in compar-
ative studies of human disease incidence and genetic variation
[45,46]. However, most of the databases (including GIDEON)
understandably have a focus on both diagnosis and treatment.
Frequently we could not find clear data (both means and
variances) for basic disease characters; for example, mortality rate
was generally only reported as rates for hospitalized patients. For
other traits, such as disease duration and effects on fertility, there
was simply very little quantitative data available.
Our results also have implications for prioritizing research on
genetic variation in response to human diseases. Malaria and
tuberculosis have been the major focus of efforts to identify genetic
variation in disease susceptibility, and these two diseases have
commanded the lion’s share of attention in this respect. In stark
contrast, a number of diseases we would predict to be associated
with high levels of variation in resistance based on their long
infectious periods and failed vaccine development efforts are
under-represented among studies of genetic diversity, even though
there is evidence to suggest that this predicted variation exists. It is
Genetic Variation in Susceptibility to Disease
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sickness, dengue fever, trichuriasis and hookworm—are classified
as ‘‘neglected tropical diseases’’ by the WHO and are diseases
associated with extreme poverty. As renewed efforts to eradicate
these neglected diseases have been invigorated by recent high-
profile donations by The Gates Foundation and others, research
on genetic variation in susceptibility may help to identify novel
strategies for controlling these infections.
Methods
Ethics statement
The research did not involve human or animal participants.
Selection of diseases
Diseases included in the study are shown in Table 1. Analyses
only included diseases with long-standing evolutionary relation-
ships with human hosts and did not include diseases that emerged
during the last century. Diseases that were not primarily human-
to-human transmitted were also excluded to minimize the
confounding effects of pathogen evolution in response to an
alternate host. For diseases that are caused by multiple etiological
agents, a single causative pathogen species was selected to be the
focus of study. Analysis of a subset of infectious diseases suggested
that only those with .2,000 citations in PubMed (as of 2010) were
likely to have been studied with respect to variation in
susceptibility; therefore, we set 2,000 citations as a threshold for
identifying diseases to include in the study. Syphilis, typhus, yellow
fever, rotavirus and shigellosis were also excluded because data on
genetic variation was insufficient. The above guidelines for disease
selection necessitated the omission of many important diseases. For
example, leishmaniasis infects over 10 million people worldwide
but was excluded because the majority of human disease is caused
by transmission from other animals and because of the
confounding effects of multiple etiological agents that are not
always clearly identified in published research. Similarly, although
HIV causes approximately 2 million deaths each year, AIDS was
not included because of its relatively recent emergence in human
populations.
Scoring genetic variation in disease susceptibility
We collected data related to genetic variation in disease
susceptibility by conducting web-based searches of several
databases including PubMed and Web of Science. We used
search terms related to genetic variation (‘‘polymorphism’’,
‘‘genetic resistance/susceptibility’’) or the type of study (‘‘twin
study’’, ‘‘case control study’’) in combination with disease and
pathogen names. We traced the references in these papers to
identify relevant prior studies, those published in books, and also
identified subsequent work using citation indices.
In assessing levels of genetic variation, we aimed to directly or
indirectly estimate the proportion of observable variation in
disease susceptibility that is due to additive genetic effects, i.e. the
heritability [47]. We focused on evidence for genetic variation in
infection rates rather than associations with disease severity or
particular symptoms contingent on disease progression. Variation
in disease expression may be due to host tolerance and recovery,
and the genetic determinants of these may or may not be related to
the genetic determinants responsible for susceptibility to infection
per se.
Because our interest was in evolutionary processes, we did not
consider genetic variation to human disease in animal model
systems, as they do not offer insight into evolutionary causes of
variation in human populations. Data came from the following
types of studies.
(i) Pedigree-based studies. These included investigations of
disease concordance rates among monozygotic versus
dizygotic twins, variance components analysis based on
extended pedigrees, and analyses of among-population
genetic variation in susceptibility. There are many caveats
and cautions related to interpreting these studies, and the
major ones are summarized in Information S1.
(ii) Marker-based studies. Evidence for variation in disease-
susceptibility loci was mostly obtained from case-control
association studies and genome-wide linkage studies. Four
classes of genetic marker were distinguished among the
marker-based studies: (a) human leukocyte antigen (HLA)
markers, (b) non-HLA immune markers, (c) neutral marker
associations (including single nucleotide polymorphism (SNP)
associations and linkage studies), and (d) directed candidate
gene markers for which there is evidence of a functional role
in disease susceptibility.
Estimates for marker-based studies were based on a weighted
mean (see below for description of weights) of the scores assigned
to each type of genetic marker on which directed studies had been
conducted.
Combining scores. As direct measurements for comparing
genetic variation in susceptibility across diseases were not
available, we employed ordinal scales to estimate relative
magnitudes of genetic variation. We ranked pedigree-based
heritability estimates on the following five-point scale: zero (non-
significant), low (less than 10 percent), intermediate (10 to 25
percent), high (25 to 50 percent), or very high (greater than 50
percent). We ranked marker-based odds ratios on a three-point
ordinal scale: zero (non-significant), low (less than two), or high
(greater than two). The overall scores for variation in susceptibility
were based on the mean of the assigned scores for pedigree- and
marker-based studies. Where only one type of evidence was
available, estimates were based on only one score.
Certainty scores. Because of the caveats mentioned above,
estimates for pedigree- and marker-based studies were
additionally assigned ‘‘certainty scores’’ based on the relative
reliability of the data reflected by the context and thoroughness of
the study being used for the estimate [44]. Certainty scores were
based on a five-point ordinal scale, with one indicating weak
evidence from poorly-conducted studies and five indicating well-
quantified data supported by multiple independent investigations.
These certainty scores were included as weights in the estimates
of genetic variation so that the overall estimates were weighted
arithmetic means of the scores for each independent line of
evidence for which data were available. We first calculated a
weighted average of the marker-based data using the estimates
and certainty scores for the four classes of genetic markers. We
then calculated the overall estimate as a weighted mean of the
heritability score and the marker-based average, each weighted
by the corresponding certainty score (the weight for the marker-
based data was the average of the weights for the 4 component
classes of markers).
Estimation of disease traits
The data on disease characteristics were compiled from online
databases related to disease (CDC, WHO, GIDEON), texts of
human infectious diseases [48–54], and, when necessary, primary
literature on particular diseases. Whenever possible, estimates
were based on data from the pre-antibiotic, pre-vaccine era to best
Genetic Variation in Susceptibility to Disease
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traits relating to the following (see Information S1 for details).
Disease effects on host fitness
(a) Mortality. Disease-induced mortality was estimated from
case fatality rates for untreated infections. Where case
fatality rates were unavailable, mortality was estimated from
the annual death rate, expressed as a percentage of the
number of annual cases.
(b) Fertility. Disease-induced male or female infertility and
offspring mortality were estimated on a four point scale (see
Information S1) based on clinical manifestations of the
disease.
Epidemiological and historical scope
(a) Lifetime risk of infection. The lifetime risk of acquiring a
disease was estimated from sero-prevalence, prevalence, and
incidence data.
(b) Geographical range. The geographical range of a disease
was estimated as the number of countries where the disease
is potentially endemic, as reported by GIDEON.
(c) Historical record of disease. The years since the disease was
first recorded in human populations was estimated from
historical reports reviewed by Kiple [51].
The type of immune response evoked by infection
(a) Incubation period. This was estimated as the number of days
from initial infection to onset of disease symptoms.
(b) Infectious period. The length of the infectious period was
estimated as the average number of days for which infected
individuals were capable of transmitting disease.
(c) Likelihood of re-infection. The lifetime risk of becoming re-
infected with a disease after initial infection was estimated
based on reports of re-infection rates.
(d) Vaccine status. Progress towards developing an effective
vaccine against a disease was estimated according to the
following scoring system: 1. Attempted, but no human trials;
2. Human clinical trials underway; 3. Partially-effective/
strain-specific vaccine in use; 4. Effective vaccine in use.
Infectious agent classification. Etiological agents of each
disease were categorized as RNA viruses, DNA viruses, bacteria,
unicellular eukaryotes (protozoa), or multicellular eukaryotes (fungi
and helminths). Infectious agent classification was treated as a class
variable in the analyses.
Pathogen transmission mode. The following transmission
modes were distinguished: sexual contact, close contact (including
transmission via air or droplet), indirect contact (including fecal-
oral or environmental transmission), and vector transmission.
Transmission mode was treated as a class variable in all analyses,
and no rankings were assigned to the classes.
Validation
The results of the data validation are presented in the
Information S1.
Susceptibility. We used three recent textbooks that reviewed
evidence of variation in susceptibility to infectious diseases
[8,13,16], and compared our estimates of genetic variation to
levels of variation documented in the textbooks by totaling the
proportion of pages in the texts devoted to variation in
susceptibility to a given disease. We compared the relationship
between our scores of variation in susceptibility and our estimates
of the disease traits to independent estimates from previous work
using Spearman’s rank correlations.
Study Effort. We tested the relationship between the scores
for variation in susceptibility and study effort for each disease by
calculating Spearman’s Rank Correlation for the scores and the
number of citations listed in the PubMed database for each
disease. The number of citations for a disease included all
references returned in a PubMed search (as of July 2010) using the
disease name as the search criterion.
Analysis
The individual effects of the disease characteristics on variation
in susceptibility were tested using Spearman’s Rank Correlation
for each of the continuous or ordinal disease traits. Effects of the
class variables (infectious agent classification and pathogen
transmission mode) were evaluated by analysis of variance
(ANOVA), using the Tukey-Kramer correction for multiple
comparisons to identify classes contributing to any observed
differences. We conducted PCA to investigate the relative
importance of the disease traits in determining the amount of
variation in susceptibility (see Results Section for details).
The explanatory variables in the data set were significantly non-
normal. We performed a log transformation of the data on the
incubation period, infectious period, and mortality variables,
which greatly improved the distributions but failed to fully restore
normality to the data. Furthermore, we were unable to identify
transformations that normalized the remaining variables in the
data set, and therefore untransformed data was used; therefore,
significance levels should be interpreted conservatively.
Unless otherwise noted, all data analyses were conducted using
SAS version 9.2 [55] and R [56].
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